Phase II trial of topotecan in patients with advanced renal cell carcinoma Academic Article Article uri icon

Overview

MeSH Major

  • CA-125 Antigen
  • Fallopian Tube Neoplasms
  • Ovarian Neoplasms
  • Peritoneal Neoplasms
  • Preoperative Care
  • Tomography, X-Ray Computed

abstract

  • Fifteen patients with advanced renal cell carcinoma were treated on a phase II trial with topotecan. None of the fourteen evaluable patients achieved a complete or partial response. Myelosuppression was the most common toxicity. Eighty percent (12 of 15) of patients experienced grade III or IV neutropenia and/or anemia. Topotecan is not efficacious in the treatment of advanced renal cell carcinoma.

publication date

  • June 1994

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1007/BF00874445

PubMed ID

  • 7860232

Additional Document Info

start page

  • 143

end page

  • 5

volume

  • 12

number

  • 2